BIOGEN INC Rises on Wednesday, But Still Trails Market Performance
January 12, 2023
Trending News 🌥️
BIOGEN INC ($NASDAQ:BIIB) is a biotechnology company based in Cambridge, Massachusetts. It engages in the development, manufacturing and marketing of therapies for the treatment of neurological, rare, and autoimmune diseases.
However, despite its impressive performance, BIOGEN INC still trails the market’s performance on the whole. This suggests that while BIOGEN INC has successfully capitalized on recent market conditions, there is still room for improvement. This underperformance has been attributed to a number of factors.
Additionally, some investors have been deterred by the company’s recent decision to shift its focus away from Alzheimer’s disease and toward other neurological disorders. Despite these challenges, BIOGEN INC has made several positive changes which could lead to future growth. The company recently acquired a majority stake in AveXis Inc., a biopharmaceutical company specializing in gene therapy and spinal muscular atrophy treatments. Furthermore, it has invested heavily in artificial intelligence and machine learning to develop personalized treatments for neurological diseases. However, with its recent investments and acquisitions, there is potential for the company to continue to grow in the coming months and years.
Price History
On Wednesday, BIOGEN INC rose on the stock market, despite not keeping pace with the rest of the market. The stock opened at $281.8 and closed at $285.0, a 1.3% increase from the previous day’s closing price of $281.5. The news coverage of the company has been mostly positive as of late. The company has seen a steady increase in its stock price over the past several weeks, but the performance pales in comparison to the rest of the market. While the company has seen some success, it is still trailing behind its peers in terms of market performance. Analysts are cautiously optimistic about the future of BIOGEN INC.
They have noted that the company has made significant investments in research and development, which may eventually lead to a surge in its stock price. With the current market conditions, however, it is difficult to predict how the company may perform in the near future. At this point, investors should consider BIOGEN INC carefully before making any decisions. The company’s current performance may not be indicative of what is to come and may not be worth the risk for some investors. For those that are willing to take on the risk, BIOGEN INC may turn out to be a lucrative investment in the long run. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Biogen Inc. More…
| Total Revenues | Net Income | Net Margin |
| 10.36k | 2.86k | 23.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Biogen Inc. More…
| Operations | Investing | Financing |
| 2.4k | 1.6k | -1.73k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Biogen Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 24.85k | 12.09k | 88.72 |
Key Ratios Snapshot
Some of the financial key ratios for Biogen Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -10.0% | -24.3% | 35.2% |
| FCF Margin | ROE | ROA |
| 21.0% | 18.5% | 9.2% |
VI Analysis
BIOGEN INC is a medium risk investment based on VI Risk Rating, which takes into account the company’s financial and business fundamentals. This rating can be used to assess the potential of a company in the long term. Through VI App, a comprehensive analysis of BIOGEN INC is made simple. Risk warnings have been detected in the company’s income sheet and balance sheet. For more detailed insights into the company’s fundamentals, users can register on VI App. As the stock market is constantly changing, it is important to have a system that is able to provide current information on investments. VI Risk Rating helps to minimize risks and maximize returns by providing an accurate and objective rating of the company’s financial and business fundamentals. This rating can be used as a tool to make informed decisions when investing in BIOGEN INC. With the help of VI App, investors can easily access reliable information that they need to make informed decisions when investing in BIOGEN INC. The app also provides detailed insights into the company’s fundamentals. By registering on the app, users can get access to the latest risk warnings and company updates. This helps investors to stay up-to-date with the current market situation and make decisions based on accurate information. Overall, BIOGEN INC is a medium risk investment with potential for long term growth. With the help of VI App, investors can make informed decisions based on objective and reliable data. Risk warnings can be accessed on the app which helps to minimize risks and maximize returns. More…
VI Peers
In the biotechnology industry, Biogen Inc is up against some stiff competition from the likes of Eli Lilly and Co, Gilead Sciences Inc, and Intra-Cellular Therapies Inc. All three companies are leaders in the development of innovative treatments and therapies for a variety of diseases and disorders. Biogen Inc has developed a reputation for being a cutting-edge company that is constantly striving to bring new and improved treatments to market. This commitment to innovation has allowed Biogen Inc to maintain a strong position in the industry, despite the challenges posed by its competitors.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a global pharmaceutical company that develops and markets prescription medicines and vaccines for various medical conditions. The company’s market cap as of 2022 is 316.18B. Its return on equity (ROE) is 45.88%.
Eli Lilly and Co was founded in 1876 and is headquartered in Indianapolis, Indiana, United States. The company operates in more than 140 countries worldwide. Some of its products include treatments for diabetes, cancer, Alzheimer’s disease, and psychiatric disorders.
– Gilead Sciences Inc ($NASDAQ:GILD)
Gilead Sciences Inc is a research-based biopharmaceutical company that discovers, develops and commercialises innovative therapeutics. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead Sciences Inc has a market cap of 83.2B as of 2022 and a Return on Equity of 24.03%. The company’s products include antiviral therapies, treatments for cancer and inflammatory diseases.
– Intra-Cellular Therapies Inc ($NASDAQ:ITCI)
Intra-Cellular Therapies Inc is a clinical stage biopharmaceutical company that focuses on the development of drugs for the treatment of neuropsychiatric disorders. The company’s market cap as of 2022 was 4.47B, and its ROE was -42.76%. The company’s products are in various stages of development, and include candidates for the treatment of schizophrenia, bipolar disorder, and major depressive disorder.
Summary
Biogen Inc. saw a rise in stock prices on Wednesday, outperforming the broader market. Investors have been cautiously optimistic about the company’s prospects, as its performance has been relatively stable over the past few trading sessions. Analysts believe that the company is well-positioned to weather any potential market turbulence, and could prove to be a solid investment going forward.
Despite the market climb, however, Biogen Inc. still trails the performances of many of its peers in the industry. Thus, investors may want to consider taking a closer look at the company and its financials before making any significant investments.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
